Irritable Bowel Syndrome (IBS) Model

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal diseases in humans. At Creative Bioarray, we can offer various animal models of IBS for our clients to help study the mechanism of IBS or evaluate the potential efficacy of your test compounds. Our comprehensive experience and expertise, coupled with a set of analytical tests have allowed us to provide reliable and high-quality data.

IBS is a highly prevalent gastrointestinal disorder, affecting 12–20% of individuals in western countries, and is characterized by a complex array of symptoms. These symptoms, which typically include abdominal pain, bloating, and altered bowel consistency, can persist for extended periods, sometimes even spanning multiple years. IBS has a significant negative impact on quality of life, often leading to missed school or work days and a reduction in work efficiency. Additionally, individuals with IBS frequently suffer from comorbid conditions such as anxiety, major depression, and chronic fatigue syndrome.

Based on the Rome IV criteria, IBS is subclassified into four distinct types: diarrhea-predominant IBS (IBS-D), constipation-predominant IBS (IBS-C), mixed IBS (IBS-M), and unclassified IBS (IBS-U), depending on the primary clinical presentation. Various risk factors have been associated with IBS, including younger age, prior gastrointestinal infections, and stressful events, among others.

Fig. 1 Main risk factors in irritable bowel syndrome (IBS)Fig. 1 Main risk factors in irritable bowel syndrome (IBS)

Our Animal Models of Irritable Bowel Syndrome (IBS)

For IBS research, currently, there are a number of well-characterized animal models. As a research partner specialized in designing pharmacology and efficacy studies for different digestive diseases, Creative Bioarray can utilize the following models for the evaluation of potential therapeutics:

Quotation and Ordering

At Creative Bioarray, we offer a comprehensive range of thoroughly characterized in vivo models, diverse administration routes, and clinically pertinent endpoints, all tailored to meet the specific needs of your digestive system projects. If you are interested in our services, please do not hesitate to contact us at any time or submit an inquiry to us directly.

Reference

  1. Napolitano, M., et al. Gut dysbiosis in irritable bowel syndrome: a narrative review on correlation with disease subtypes and novel therapeutic implications. Microorganisms, 2023, 11(10): 2369.

For research use only. Not for any other purpose.